EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tumor organoid-immune cell co-culture systems for precision oncology

Lei Cai, Yunfeng Xiao, Feihong Xie, Zongke Yang

Frontiers in Cell and Developmental Biology · 23.07.2026 · 14

DOI: 10.3389/fcell.2026.1865487 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 23.07.2026. Verfasst von Lei Cai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Three-dimensional tumor organoids, particularly patient-derived organoids (PDOs), recapitulate key morphological, genetic, and functional features of original tumors. Co-culture with immune cells enables studies of the tumor immune microenvironment (TIME) and holds promise for personalized immunotherapy. In this review, we critically evaluate established methodologies for tumor organoid-immune cell co-culture, including reductionist, holistic (tumor slice culture and air-liquid interface), and organoid-on-a-chip approaches. We provide quantitative benchmarking of success rates, immune cell persistence, and predictive accuracy, and discuss contradictory findings, reproducibility challenges, and technical barriers that limit clinical translation. We also analyze how these systems reveal mechanisms of antitumor immunity and immune escape, and assess their applications in immune checkpoint blockade screening, adoptive cell therapy (CAR-T, CAR-NK, γδ T cells), and emerging “organoid+” technologies including spatial transcriptomics, AI-assisted imaging, and machine learning. Finally, we address ethical, regulatory, and standardization issues. Despite substantial progress, current systems face major limitations—including batch variability, loss of native heterogeneity, insufficient vascularization, and lack of systemic immune modeling—that must be overcome before clinical adoption.

Schlagwörter

Stichwörter der Autor:innen

immune cell co-cultureimmunotherapypatient-derived organoidsprecision oncologytumor immune microenvironmenttumor organoids

Autor:innen und Institutionen

  • Department of Breast Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
  • Department of Pediatric Surgery, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
  • Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Urology, Dianjiang People's Hospital of Chongqing, Chongqing, China.

Zitieren

APA

Cai, L., Xiao, Y., Xie, F., & Yang, Z. (2026). Tumor organoid-immune cell co-culture systems for precision oncology. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1865487

Vancouver

Cai L, Xiao Y, Xie F, Yang Z. Tumor organoid-immune cell co-culture systems for precision oncology. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1865487

BibTeX
@article{Cai2026,
  author = {Cai, Lei and Xiao, Yunfeng and Xie, Feihong and Yang, Zongke},
  title = {Tumor organoid-immune cell co-culture systems for precision oncology},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2026},
  volume = {14},
  doi = {10.3389/fcell.2026.1865487}
}
Kostenlos starten →